Portola Pharma

PTLA NASDAQ
26.64
-0.24
-0.89%
盘后: 26.64 0 0.00% 17:05 07/19 EDT
开盘
26.90
昨收
26.88
最高
27.08
最低
26.58
成交量
75.04万
成交均量(3M)
97.39万
52周最高
42.17
52周最低
14.81
换手率
1.10%
市值
18.14亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Portola Pharma PTLA股票价格,Portola Pharma股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
展开 >

最近浏览

名称
价格
涨跌幅